Roman Rohner Profile
Roman Rohner

@rorohner

Followers
26
Following
10
Media
0
Statuses
14

Resident in Neuroradiology @inselgruppe | Clinical Research @StrokeBern @ScanNeuroradBE

Joined April 2022
Don't wanna be here? Send us removal request.
@StrokeAHA_ASA
Stroke AHA/ASA
4 months
🌟 @ELAN_Trial subanalysis shows that prior reperfusion strategy does not modify outcome in early vs late start of anticoagulants in acute ischemic stroke patients. @TakeshiYoshimo4 @Yperzeele_L @TweetNeuroLine @rorohner @mbgoeldlin @FishingNeurons
1
9
12
@adnan_mujanovic
Adnan Mujanović
1 year
@StrokeAHA_ASA
Stroke AHA/ASA
1 year
🧵The significance of delayed reperfusion post-EVT in predicting response to adjunctive therapies is not known. Predicting the evolution of reperfusion post-EVT could identify promising candidates for adjunctive anti-thrombotic, lytic, or neuroprotectant therapies. #SVIN24
2
11
24
@adnan_mujanovic
Adnan Mujanović
1 year
Look for the DOTs ⚪️⚫️ Flat-panel non-contrast CT could be enough to indicate which patients will have persistent hypoperfusion (and poor outcome) post-EVT ⬇️⬇️⬇️ https://t.co/2ds4ggADoP
2
20
49
@Eikeip
Eike Piechowiak
1 year
Join us (@TDobrocky @JrgenBeck) in Singapore (November 14th - 17th) for a comprehensive and interactive session on SIH. All aspects of the disease including a systematic diagnostic work-up, transvenous CSF venous fistula embolization and surgical management will be covered.
1
12
24
@FishingNeurons
Urs Martin Fischer
1 year
Early anticoagulation in ischaemic stroke patients with haemorrhagic transformation? @StrokeBern
@CircAHA
Circulation
1 year
1
14
29
@CircAHA
Circulation
1 year
@CircAHA
Circulation
1 year
In this subgroup analysis of the ELAN trial, there was no major safety concerns or heterogeneity in treatment effect of early vs late initiation of DOAC in AF patients with ischemic stroke and hemorrhagic transformation.
0
6
14
@JAMANeuro
JAMA Neurology
1 year
ELAN trial post-hoc analysis: Early DOAC treatment after ischemic strokes was not associated with a higher rate of adverse events, especially sICH, regardless of infarct size group. Persons with major stroke seem to benefit most (OR 0.52 (0.21 to 1.18)). https://t.co/732s1GeclJ
2
27
82
@inselgruppe
Insel Gruppe
1 year
Early start of treatment with blood thinners after stroke & atrial fibrillation reduces risk of recurrent stroke also in large infarcts & haemorrhagic transformation. More: https://t.co/ReQYL7CY4q https://t.co/zoDON792RK. #InselGruppe #StrokeResearch #Neurology #Neuroradiology
0
19
30
@adnan_mujanovic
Adnan Mujanović
1 year
❗️A prespecified subanalysis of the @ELAN_Trial is here❗️No treatment effect of hemorrhagic transformation on early versus late DOAC initiation among stroke patients with AFib ✅️ Critical data for DOAC timing after stroke 💊 Congrats @rorohner & team!
@FishingNeurons
Urs Martin Fischer
1 year
Can we start direct oral anticoagulants early after ischemic stroke in people with atrial fibrillation AND hemorrhagic transformation? Check our article in CIRCULATION! ⁦⁦⁦@rorohner⁩ ⁦@mbgoeldlin⁩ ⁦@inselgruppe⁩ ⁦⁦@unibern
1
17
24
@FishingNeurons
Urs Martin Fischer
1 year
Can we start direct oral anticoagulants early after ischemic stroke in people with atrial fibrillation AND hemorrhagic transformation? Check our article in CIRCULATION! ⁦⁦⁦@rorohner⁩ ⁦@mbgoeldlin⁩ ⁦@inselgruppe⁩ ⁦⁦@unibern
Tweet card summary image
ahajournals.org
BACKGROUND: Whether hemorrhagic transformation (HT) modifies the treatment effect of early compared with late initiation of direct oral anticoagulation in people with ischemic stroke and atrial...
1
22
50
@mbgoeldlin
Martina Göldlin
1 year
Should we start anticoagulation early even in persons w major stroke? ➡️ Our newest paper in @JAMANeuro explores the interaction of early #DOAC therapy and infarct size in the @ELAN_Trial @FishingNeurons
@JAMANeuro
JAMA Neurology
1 year
ELAN trial post-hoc analysis: Early DOAC treatment after ischemic strokes was not associated with a higher rate of adverse events, especially sICH, regardless of infarct size group. Persons with major stroke seem to benefit most (OR 0.52 (0.21 to 1.18)). https://t.co/ZA9svFW2nS
0
18
33
@mbgoeldlin
Martina Göldlin
2 years
🧵2/3 🙏 @FishingNeurons, @rorohner , Jesse Dawson & Markus Kneihsl for leading this international team effort! @StrokeBern 👏 to @rorohner for first #ESOC2024 presentation with simultaneous publication!
1
1
2
@FishingNeurons
Urs Martin Fischer
2 years
Congratulations to Roman Rohner, Markus Kneihsl and all the ELAN collaborators for all their efforts. Such a wonderful team! The paper has just been published in @CircAHA !
@adnan_mujanovic
Adnan Mujanović
2 years
@ELAN_Trial RCT subanalysis ⏰️ Early vs late start of anticoagulations does not seem to have treatment effect heterogeneity on safety outcomes (sICH, recurrent stroke, mRS>3) ✅️ However, 25%⬆️ risk for mRS>3 in people with PH! @rorohner #ESOC2024 #VoiceOfStroke
0
18
44
@adnan_mujanovic
Adnan Mujanović
2 years
@ELAN_Trial RCT subanalysis ⏰️ Early vs late start of anticoagulations does not seem to have treatment effect heterogeneity on safety outcomes (sICH, recurrent stroke, mRS>3) ✅️ However, 25%⬆️ risk for mRS>3 in people with PH! @rorohner #ESOC2024 #VoiceOfStroke
0
16
30